0.46

9.79% 0.041

Nextcure Inc (NXTC)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché NXTC Giù? Forum Previsione

Precedente Chiudi:

$0.419

Aprire:

$0.4301

Volume 24 ore:

321.69K

Relative Volume:

2.42

Capitalizzazione di mercato:

$10.33M

Reddito:

Utile/perdita netta:

$-58.52M

Rapporto P/E:

-0.2201

EPS:

-2.09

Flusso di cassa netto:

$-45.03M

1 W Prestazione:

+27.35%

1M Prestazione:

-19.16%

6M Prestazione:

-66.91%

1 anno Prestazione:

-64.34%

Intervallo 1D:

$0.395

$0.499

Intervallo di 1 settimana:

$0.3499

$0.499

Portata 52W:

$0.224

$1.8199

Nextcure Inc Stock (NXTC) Company Profile

Nome

Nextcure Inc

Settore

Healthcare (1154)

Industria

Biotechnology (677)

Telefono

240-399-4900

Indirizzo

9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD

Dipendente

Cinguettio

@nextcureinc

Prossima data di guadagno

2025-03-07

Ultimi documenti SEC

NXTC's Discussions on Twitter

Confronta NXTC con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
NXTC Nextcure Inc	0.46	10.33M	0	-58.52M	-45.03M	-2.09
VRTX Vertex Pharmaceuticals Inc	493.84	122.76B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	602.64	61.38B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	614.76	36.37B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.56	30.12B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	244.90	24.70B	3.81B	-644.79M	-669.77M	-6.24

Nextcure Inc Stock (NXTC) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2022-11-04	Downgrade	Ladenburg Thalmann	Buy → Neutral
2022-03-01	Iniziato	Ladenburg Thalmann	Buy
2021-03-05	Aggiornamento	Truist	Hold → Buy
2021-01-15	Downgrade	BofA Securities	Neutral → Underperform
2020-07-16	Aggiornamento	The Benchmark Company	Hold → Buy
2020-07-13	Downgrade	ROTH Capital	Buy → Neutral
2020-07-13	Downgrade	SunTrust	Buy → Hold
2020-06-01	Downgrade	BofA/Merrill	Buy → Neutral
2020-06-01	Downgrade	The Benchmark Company	Buy → Hold
2020-05-26	Iniziato	JMP Securities	Mkt Outperform
2020-03-24	Iniziato	The Benchmark Company	Buy
2020-03-02	Iniziato	ROTH Capital	Buy
2020-01-13	Iniziato	SunTrust	Buy
2019-12-05	Iniziato	Needham	Buy
2019-11-26	Iniziato	BTIG Research	Buy
2019-07-09	Iniziato	BofA/Merrill	Buy
2019-06-03	Iniziato	Morgan Stanley	Overweight
2019-06-03	Iniziato	Piper Jaffray	Overweight

Mostra tutto

Nextcure Inc Borsa (NXTC) Ultime notizie

08:02 AM

Is Nextcure Inc’s -69.93% Fall This Year Is A Better Investing Opportunity? - Marketing Sentinel

08:02 AM

Apr 24, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 24, 2025

Apr 10, 2025

NextCure Updates Presentation on LNCB74 Clinical Trial - TipRanks

Apr 10, 2025

NextCure stock hits 52-week low at $0.3 amid sharp decline - Investing.com Australia

Apr 10, 2025

Apr 09, 2025

NextCure stock hits 52-week low at $0.3 amid sharp decline By Investing.com - Investing.com South Africa

Apr 09, 2025

Apr 04, 2025

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference - The Manila Times

Apr 04, 2025

Cancer Therapy Breakthrough? NextCure's Major Presentation at Needham Healthcare Conference - Stock Titan

Apr 04, 2025

Apr 03, 2025

CLASS ACTION UPDATE for PLAN, NXTC and BTU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire

Apr 03, 2025

Apr 01, 2025

NextCure stock plunges to 52-week low, hits $0.46 - Investing.com India

Apr 01, 2025

NextCure stock plunges to 52-week low, hits $0.46 By Investing.com - Investing.com Australia

Apr 01, 2025

Mar 25, 2025

NextCure stock hits 52-week low at $0.55 amid market challenges By Investing.com - Investing.com South Africa

Mar 25, 2025

NextCure stock hits 52-week low at $0.55 amid market challenges - Investing.com India

Mar 25, 2025

Mar 20, 2025

ROSEN, A LEADING LAW FIRM, Reminds NextCure, Inc. Investors of Important November 20 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – NXTC - Business Wire

Mar 20, 2025

Mar 19, 2025

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Mar 19, 2025

Mar 18, 2025

H.C. Wainwright maintains Buy rating, $3 target on NextCure stock - Investing.com India

Mar 18, 2025

H.C. Wainwright maintains Buy rating, $3 target on NextCure stock By Investing.com - Investing.com South Africa

Mar 18, 2025

NextCure’s (NXTC) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Mar 18, 2025

Mar 17, 2025

NextCure stock plunges to 52-week low at $0.66 amid market challenges - Investing.com Australia

Mar 17, 2025

Mar 13, 2025

NextCure (NXTC) Projected to Post Quarterly Earnings on Thursday - Defense World

Mar 13, 2025

Mar 10, 2025

NextCure Provides Business Update and Reports Full Year 2024 Financial Results - The Manila Times

Mar 07, 2025

Mar 06, 2025

NextCure, Inc. Completes First Cohort of Phase 1 Trial for LNCB74 and Plans for Backfill Cohorts - Nasdaq

Mar 06, 2025

Can NextCure's $68M Cash Support Its Cancer Drug Development Through 2026? - StockTitan

Mar 06, 2025